// App-Quantinova.ai

Su1058 : Early Stopping Rules for Faldaprevir Plus Pegylated Interferon ?-2A and Ribavirin in Treatment-NaiVE Patients: Exploratory Study of Pooled Data From Phase III Trials

Researchers

Presenter

  • Douglas T. Dieterich

Principal Investigators

  • Masao Omata

  • Armando Abergel

  • Makoto Kuboki

  • Armando Carvalho

  • Cheng-Yuan Peng

  • Manuel Romero-Gomez

  • David Wright

  • Jerry O. Stern

  • Wulf Bocher

  • George Kukolj

  • Parvez S. Mantry

  • John-Paul Gallivan

  • Joseph Scherer

  • Donald M. Jensen

  • Christoph Sarrazin

  • Javier Crespo

  • Edward Tam

  • Jean-Francois Dufour

  • Eric M. Yoshida

  • Shuhei Nishiguchi

  • Marc Bourliere

Medical Centers

  • Centre Hospitalier Universitaire Clermont-Ferrand, Clermont-Ferrand, France

  • Hospital de Valme, Seville, Spain

  • The Liver Institute at Methodist Dallas Medical Center, Dallas, TX

  • Mount Sinai School of Medicine, New York, NY

  • University Clinic for Visceral Surgery and Medicine, Berne, Switzerland

  • China Medical University Hospital, Taichung, Taiwan

  • Kurashiki Medical Clinic, Okayama, Japan

  • Hospitais Da Universidade De Coimbra, Coimbra, Portugal

  • The University of British Columbia, Vancouver, BC, Canada

  • LAIR Centre, Vancouver, BC, Canada

  • Hyogo College of Medicine, Hyogo, Japan

  • Yamanishi Central and Kita Hospitals, Yamanishi, Japan

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Goethe University, Frankfurt, Germany

  • Medical University of Vienna, Vienna, Austria

  • Central Texas Clinical Research, Austin, TX

  • The University of Chicago Medical Center, Chicago, IL

Locations

  • Canada

  • Taiwan

  • Japan

  • Austria

  • Spain

  • Germany

  • Switzerland

  • United States

  • Portugal

  • France

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Interferon

  • Sustained virological response

Drug/Treatment

  • Faldaprevir-sodium

  • Interferon

  • Ribavirin

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved